tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Feb 14;10(2):291.
doi: 10.3390/vaccines10020291.
Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
Yfat Yahalom-Ronen[SUP] 1 [/SUP], Noam Erez[SUP] 1 [/SUP], Morly Fisher[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Boaz Politi[SUP] 1 [/SUP], Hagit Achdout[SUP] 1 [/SUP], Sharon Melamed[SUP] 1 [/SUP], Itai Glinert[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Inbar Cohen-Gihon[SUP] 2 [/SUP], Ofir Israeli[SUP] 2 [/SUP], Marina Izak[SUP] 3 [/SUP], Michal Mandelboim[SUP] 4 [/SUP], Yoseph Caraco[SUP] 5 [/SUP], Noa Madar-Balakirski[SUP] 6 [/SUP], Adva Mechaly[SUP] 1 [/SUP], Eilat Shinar[SUP] 3 [/SUP], Ran Zichel[SUP] 7 [/SUP], Daniel Cohen[SUP] 8 [/SUP], Adi Beth-Din[SUP] 2 [/SUP], Anat Zvi[SUP] 2 [/SUP], Hadar Marcus[SUP] 7 [/SUP], Tomer Israely[SUP] 1 [/SUP], Nir Paran[SUP] 1 [/SUP]
Affiliations
Abstract
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife[SUP]®[/SUP] (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife[SUP]®[/SUP] vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife[SUP]®[/SUP] vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife[SUP]®[/SUP]-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
Keywords: BriLife®; COVID-19; SARS-CoV-2; VOC; VSV; convalescent; neutralization; vaccine; variants.
. 2022 Feb 14;10(2):291.
doi: 10.3390/vaccines10020291.
Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
Yfat Yahalom-Ronen[SUP] 1 [/SUP], Noam Erez[SUP] 1 [/SUP], Morly Fisher[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Boaz Politi[SUP] 1 [/SUP], Hagit Achdout[SUP] 1 [/SUP], Sharon Melamed[SUP] 1 [/SUP], Itai Glinert[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Inbar Cohen-Gihon[SUP] 2 [/SUP], Ofir Israeli[SUP] 2 [/SUP], Marina Izak[SUP] 3 [/SUP], Michal Mandelboim[SUP] 4 [/SUP], Yoseph Caraco[SUP] 5 [/SUP], Noa Madar-Balakirski[SUP] 6 [/SUP], Adva Mechaly[SUP] 1 [/SUP], Eilat Shinar[SUP] 3 [/SUP], Ran Zichel[SUP] 7 [/SUP], Daniel Cohen[SUP] 8 [/SUP], Adi Beth-Din[SUP] 2 [/SUP], Anat Zvi[SUP] 2 [/SUP], Hadar Marcus[SUP] 7 [/SUP], Tomer Israely[SUP] 1 [/SUP], Nir Paran[SUP] 1 [/SUP]
Affiliations
- PMID: 35214749
- DOI: 10.3390/vaccines10020291
Abstract
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife[SUP]®[/SUP] (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife[SUP]®[/SUP] vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife[SUP]®[/SUP] vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife[SUP]®[/SUP]-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
Keywords: BriLife®; COVID-19; SARS-CoV-2; VOC; VSV; convalescent; neutralization; vaccine; variants.